Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus Whole-Brain Radiation Therapy vs Whole-Brain Radiation Therapy Alone in Brain Metastases from Non-Small Cell Lung Cancer
2010-019637-96Phase 2Terminated
- Sponsor
- YM BioSciences
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nimotuzumab in brain metastases and non-small cell lung cancer (NSCLC) (2 arms), sponsored by YM BioSciences. Primary endpoints: Intracranial disease progression at 6 months and Overall survival. Started Oct 2010; status: terminated.
02
Drugs
nimotuzumab
03
Conditions
brain metastasesnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-019637-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019637-96.